NCT05932641View on ClinicalTrials.gov

Study of AZD3152 Intramuscular Injection or Intravenous Infusion in Healthy Japanese Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 31, 2023

Primary Completion Date

December 5, 2024

Study Completion Date

December 5, 2024

Conditions
COVID-19, SARS-CoV-2
Interventions
BIOLOGICAL

AZD3152 (Cohort 1)

Single dose of AZD3152 300 mg IM on Visit 2 Day 1

BIOLOGICAL

Placebo (Cohort 1)

Single dose of Placebo IM on Visit 2 Day 1

BIOLOGICAL

AZD3152 (Cohort 2)

Single dose of AZD3152 600 mg IM on Visit 2 Day 1

BIOLOGICAL

Placebo (Cohort 2)

Single dose of Placebo IM on Visit 2 Day 1

BIOLOGICAL

AZD3152 (Cohort 3)

Single dose of AZD3152 1200 mg IV on Visit 2 Day 1

BIOLOGICAL

Placebo (Cohort 3)

Single dose of Placebo IM on Visit 2 Day 1

Trial Locations (1)

812-0025

Research Site, Fukuoka

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY